Welcome to our dedicated page for Amarin SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amarin Corporation plc (NASDAQ: AMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amarin is a global pharmaceutical company focused on cardiovascular disease and the commercialization of its icosapent ethyl product, VASCEPA/VAZKEPA. Its filings offer detailed insight into how the business is structured, how key agreements are arranged and how financial performance is reported.
Investors can use this page to review current reports on Form 8-K, where Amarin discloses material events such as quarterly financial results, global restructuring actions and major licensing arrangements. For example, a Form 8-K describes the exclusive long-term license and supply agreement with Recordati to develop and commercialize VAZKEPA in 59 European-focused countries, as well as the associated global restructuring plan aimed at reducing operating costs. Other 8-K filings address financial results for specific quarters and executive appointments.
In addition to 8-Ks, Amarin’s periodic reports on Form 10-K and Form 10-Q (referenced in its press releases) contain more comprehensive discussions of revenue from VASCEPA/VAZKEPA, licensing and royalty income, operating expenses, restructuring charges and risk factors related to cardiovascular therapeutics and global commercialization. These documents are central for understanding the company’s balance sheet, cash position, cost structure and exposure to clinical, regulatory and market risks.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as the nature of material agreements, the scale and timing of restructuring plans, and the implications of licensing deals for future revenue streams. Users can quickly identify items related to Amarin’s cardiovascular franchise, including references to VASCEPA/VAZKEPA, global partners and restructuring initiatives, while retaining the ability to drill down into the full SEC documents for complete context.
Amarin director Patrice Eadon Bonfiglio reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, 2026, previously granted restricted stock units vested, resulting in the acquisition of 838 ADSs through a derivative exercise. In connection with this vesting, the company withheld 403 ADSs at a value of $14.98 per ADS to cover tax obligations, which the filing notes is not a market sale under Rule 16b-3. After these transactions, Bonfiglio directly owns 836 ADSs. Footnotes explain that one ADS represents twenty ordinary shares following an ADS ratio change and that the RSUs were granted under Amarin’s 2020 Stock Incentive Plan, vesting in three equal annual installments.
Amarin Corporation director Paul Cohen reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, 838 ADS were acquired at $0.00 per share through the exercise of Restricted Stock Units, reflecting an equity award vesting. On the same date, 403 ADS at $14.98 per share were withheld by Amarin to cover tax liabilities tied to this vesting, which a footnote clarifies is not a market sale of securities under Rule 16b‑3. Following these transactions, Cohen directly held 1,239 ADS. Footnotes note a prior ADS ratio change, with each ADS now representing twenty ordinary shares and each RSU representing a contingent right to receive twenty ordinary shares or cash.
Amarin director Louis Sterling III reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, he exercised 838 Restricted Stock Units (RSUs), receiving 838 ADSs at a stated price of $0.00 per ADS.
On the same date, 403 ADSs were withheld by Amarin to cover tax liabilities related to the vesting, at a value of $14.98 per ADS, which the company notes is not a market sale of securities. After these transactions, Sterling’s direct holdings increased to 4,452 ADSs.
Footnotes explain that Amarin previously implemented an ADS ratio change so that one ADS represents twenty ordinary shares, and that the RSUs were part of a 2,514-unit grant made on April 18, 2024, vesting in three equal annual installments under the 2020 Stock Incentive Plan.
Amarin director Odysseas D. Kostas reported routine equity compensation activity involving American Depositary Shares (ADS). On April 18, 2026, he exercised 838 Restricted Stock Units (RSUs), acquiring 838 ADS at a stated price of $0.00 per ADS.
In connection with this vesting, 403 ADS were withheld by Amarin to cover related tax liabilities, as described in the filing as a tax-withholding disposition under Rule 16b-3, not a market sale. After these transactions, Kostas directly held 1,239 ADS.
The RSUs stem from a grant of 2,514 RSUs made on April 18, 2024 under Amarin’s 2020 Stock Incentive Plan, vesting in three equal installments on April 18, 2025, 2026, and 2027. Each RSU represents a contingent right to receive twenty ordinary shares or cash, and all reported amounts reflect a prior ADS ratio change.
Amarin Corporation director Diane E. Sullivan reported compensation-related share activity involving American Depositary Shares (ADS) on April 18, 2026. She exercised 838 Restricted Stock Units (RSUs) into 838 ADS at a stated price of $0.00 per ADS, reflecting a scheduled vesting under the company’s 2020 Stock Incentive Plan. To cover tax liabilities from this vesting, 403 ADS were withheld by Amarin at $14.98 per ADS, which the company notes was not a market sale. Following these transactions, Sullivan directly holds 1,239 ADS. Footnotes explain that each RSU represents a contingent right to receive twenty ordinary shares or cash and that the reported amounts reflect a prior ADS ratio change.
Amarin Corporation director Keith Horn reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, 2026, 838 ADSs were issued upon the exercise of 838 Restricted Stock Units (RSUs), reflecting an earlier grant under Amarin’s 2020 Stock Incentive Plan. On the same date, 403 ADSs were withheld by Amarin to cover tax liabilities tied to this vesting, at an indicated value of $14.98 per ADS, which the company clarifies is not a market sale under Rule 16b-3. After these transactions, Horn directly owned 1,239 ADSs. Footnotes note that one ADS currently represents twenty ordinary shares following a prior ADS ratio change and that the original RSU grant totaled 2,514 units vesting in three equal annual installments.
Amarin Corporation director Oliver O’Connor reported routine equity compensation activity involving American Depositary Shares (ADSs). On April 18, he acquired 838 ADSs through the vesting and conversion of Restricted Stock Units, while 438 ADSs were withheld by the company to cover tax obligations.
After these transactions, he directly held 1,239 ADSs. A prior grant on April 18, 2024 covered 2,514 RSUs vesting in three equal installments on April 18, 2025, 2026 and 2027. Each RSU represents a contingent right to receive one ADS, and each ADS currently represents twenty ordinary shares after an ADS ratio change.
Amarin Corporation is asking shareholders at its May 13, 2026 AGM to re-elect seven directors, approve 2025 executive pay on an advisory basis, and reappoint Ernst & Young as auditor. The company highlights a 2025 restructuring, ending the year with $303 million in cash, no debt, and positive Q4 2025 cash flow, with expected annual savings of $70 million.
Shareholders are asked to renew authority for the Board to issue new ordinary shares up to a nominal £37,750,000 (about 18% of existing share capital) and to approve an amended 2020 Stock Incentive Plan adding 15,000,000 ordinary shares to the reserve. A special resolution would also allow issuances for cash without UK pre-emption rights up to a nominal £20,970,000 (about 10% of existing share capital), and another would permit electronic AGM notices via a website to cut printing and mailing costs.
Amarin Corporation CFO Peter L. Fishman reported routine equity compensation activity involving Restricted Stock Units (RSUs) and American Depositary Shares (ADSs). On April 1, 2026, 125 RSUs previously granted under the company’s stock plan were exercised into 125 ADSs at an exercise price of $0.00 per share.
Of these ADSs, 62 shares were withheld by Amarin at $14.46 per share to cover tax liabilities related to the vesting, as permitted under Rule 16b-3 and described as not being a market sale. Following these transactions, Fishman holds 6,220 ADSs directly, reflecting a small, compensation-driven adjustment to his position.